BioAtla (NASDAQ:BCAB) Stock Price Crosses Below 50 Day Moving Average – Time to Sell?

BioAtla, Inc. (NASDAQ:BCAB – Get Free Report)’s share price passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $1.61 and traded as low as $1.56. BioAtla shares last traded at $1.56, with a volume of 564 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioAtla in a research report on Monday, August 31st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $200.00.

Read Our Latest Analysis on BioAtla

BioAtla Stock Down 7.7%

The stock has a market capitalization of $2.60 million, a P/E ratio of -0.06 and a beta of 0.53. The business has a 50-day simple moving average of $1.61 and a two-hundred day simple moving average of $4.46.

BioAtla (NASDAQ:BCAB – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($8.50) by $8.64. The firm had revenue of $6.50 million for the quarter, compared to the consensus estimate of $6.50 million.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in BioAtla stock. ADAR1 Capital Management LLC increased its holdings in BioAtla, Inc. (NASDAQ:BCAB – Free Report) by 24.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 228,107 shares of the company’s stock after purchasing an additional 45,000 shares during the quarter. ADAR1 Capital Management LLC owned approximately 13.74% of BioAtla worth $37,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

(Get Free Report)

BioAtla, Inc. was a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company used its Conditionally Active Biologics (CAB) platform to design antibody-based medicines intended to become active primarily within the tumor microenvironment, with the goal of improving treatment effectiveness while limiting effects on healthy tissue. BioAtla’s investigational pipeline included antibody-drug conjugates and immune-modulating therapies. Its lead programs included mecbotamab vedotin, an antibody-drug conjugate designed to target AXL, and ozuriftamab vedotin, an investigational therapy directed at ROR2.

Featured Stories

Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.